News ASCO: Novartis touts Kisqali adjuvant breast cancer data Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte
R&D Inside the new world of healthcare data These days, real-world data collection is in vogue and not hard to come by in healthcare research.
